反应方程式
[CH3:1][C@H:2]1[CH2:7][NH:6][C@H:5]([CH3:8])[CH2:4][NH:3]1.Cl[C:10]1[N:11]([CH2:32][CH:33]([CH3:35])[CH3:34])[C:12]2[C:17]([N:18]=1)=[C:16]([N:19]1[CH2:24][CH2:23][O:22][CH2:21][CH2:20]1)[N:15]=[C:14]([C:25]1[CH:26]=[N:27][C:28]([NH2:31])=[N:29][CH:30]=1)[N:13]=2>CN1CCCC1=O>[CH3:1][C@H:2]1[CH2:7][NH:6][C@H:5]([CH3:8])[CH2:4][N:3]1[C:10]1[N:11]([CH2:32][CH:33]([CH3:35])[CH3:34])[C:12]2[C:17]([N:18]=1)=[C:16]([N:19]1[CH2:20][CH2:21][O:22][CH2:23][CH2:24]1)[N:15]=[C:14]([C:25]1[CH:26]=[N:27][C:28]([NH2:31])=[N:29][CH:30]=1)[N:13]=2参与物
4
反应条件
- 温度
- 150 °C
实验过程
trans-2,5-Dimethylpiperazine (150 mg, 1.3 mmol) and N-methylpyrrolidone (1 ml) were added to 5-(8-chloro-9-isobutyl-6-morpholin-4-yl-9H-purin-2-yl)pyrimidin-2-amine (100 mg, 0.26 mmol) and the resulting mixture was stirred at 150° C. for 48 hours. The reaction mixture was cooled and partitioned with methylene chloride and water, the organic layer was dried over magnesium sulfate, and the solvent was concentrated under reduced pressure. The residue was purified by preparative HPLC (column, NOMURA Develosil Combi-RP-5; mobile phase, acetonitrile/water/formic acid) to give the title compound (120 mg) as a pale yellow solid.
后处理
- temperatureThe reaction mixture was cooled
- custompartitioned with methylene chloride and water
- dry with materialthe organic layer was dried over magnesium sulfate
- concentrationthe solvent was concentrated under reduced pressure
- customThe residue was purified by preparative HPLC (column, NOMURA Develosil Combi-RP-5; mobile phase, acetonitrile/water/formic acid)
来源与证据
- ORD记录
- ord-65687781f1df46848595e6d42acdc07c
- 来源数据集
- uspto-grants-2012_01
- 专利号
- US08097622B2
关联笔记
加载中…